{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:47:06Z","timestamp":1792900026810,"version":"4.5.0"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.5090-24","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:10:42Z","timestamp":1743790242000},"page":"2995-2999","source":"Crossref","is-referenced-by-count":4,"title":["Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature"],"prefix":"10.2169","volume":"64","author":[{"given":"Koki","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Japan"},{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Demura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Oi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 381: 320-332, 2013.","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 10: 1238, 2019.","DOI":"10.3389\/fimmu.2019.01238"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci  E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine 69: 504-507, 2020.","DOI":"10.1007\/s12020-020-02272-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 79: 1081-1088, 2018.","DOI":"10.1016\/j.jaad.2018.07.008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 57: 664-669, 2018.","DOI":"10.1111\/ijd.13984"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous pemphigoid as pruritus in the elderly: a common presentation. JAMA Dermatol 149: 950-953, 2013.","DOI":"10.1001\/jamadermatol.2013.756"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Molina GE, Reynolds KL, Chen ST. Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study. Br J Dermatol 183: 1126-1128, 2020.","DOI":"10.1111\/bjd.19313"},{"key":"8","unstructured":"8. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402: 203-234, 2023."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Reinhold D, Biton A, Goihl A, et al. Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann N Y Acad Sci 1110: 402-409, 2007.","DOI":"10.1196\/annals.1423.042"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Broxmeyer HE, Hoggatt J, O&apos;Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 18: 1786-1796, 2012.","DOI":"10.1038\/nm.2991"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018.","DOI":"10.1056\/NEJMra1703481"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pujalte-Martin M, Rocher F, Cardot-Leccia N, Giacchero D, Borchiellini D. Immune checkpoint inhibitor-induced bullous pemphigoid: towards a new class of drug-drug interaction? Eur J Cancer 138: 122-124, 2020.","DOI":"10.1016\/j.ejca.2020.07.027"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sadik CD, Langan EA, Gutzmer R, et al. Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol 11: 588582, 2021.","DOI":"10.3389\/fimmu.2020.588582"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2: 442-444, 2016.","DOI":"10.1016\/j.jdcr.2016.05.009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist 23: 1119-1126, 2018.","DOI":"10.1634\/theoncologist.2018-0128"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Guan S, Zhang L, Zhang J, Song W, Zhong D. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy. Front Immunol 13: 1068978, 2023.","DOI":"10.3389\/fimmu.2022.1068978"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hara K, Yamasaki K, Yamada S, Yatera K. Bullous pemphigoid in a patient treated with pembrolizumab. Intern Med 59: 139-140, 2020.","DOI":"10.2169\/internalmedicine.3264-19"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Adachi E, Honda T, Nonoyama S, et al. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab. J Dermatol 46: e232-e233, 2019.","DOI":"10.1111\/1346-8138.14813"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sugawara A, Koga H, Abe T, Ishii N, Nakama T. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment. J Dermatol 48: 401-404, 2021.","DOI":"10.1111\/1346-8138.15693"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chatterjee T, Rashid TF, Syed SB, Roy M. Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report. Cureus 14: e21770, 2022.","DOI":"10.7759\/cureus.21770"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4: 383-389, 2016.","DOI":"10.1158\/2326-6066.CIR-15-0123"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Muto Y, Namikawa K, Fujiwara Y, et al. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: a case report. J Dermatol 47: e9-e11, 2020.","DOI":"10.1111\/1346-8138.15140"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cosimati A, Rossi L, Didona D, Forcella C, Didona B. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: a case report and review of literature. J Oncol Pharm Pract 27: 727-733, 2021.","DOI":"10.1177\/1078155220946370"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Quach HT, Dewan AK, Davis EJ, et al. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol 5: 906-908, 2019.","DOI":"10.1001\/jamaoncol.2019.0046"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol 79: 1047-1052, 2018.","DOI":"10.1016\/j.jaad.2018.05.035"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 83: 1255-1268, 2020.","DOI":"10.1016\/j.jaad.2020.03.132"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy. Am J Clin Dermatol 19: 345-361, 2018.","DOI":"10.1007\/s40257-017-0336-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5090-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:27:06Z","timestamp":1760761626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5090-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":27,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5090-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"5090-24"}}